Name | Oaks, The |
---|---|
Location | 4525 Acushnet Avenue, New Bedford, Massachusetts |
Certified By | Medicare and Medicaid |
No. of Certified Beds | 122 |
Occupancy Rate | 67.21% |
Medicare ID (CCN) | 225328 |
Legal Business Name | New Bedford Medical Investors, Llc |
Ownership Type | For Profit - Limited Liability Company |
NPI Number | 1104886613 |
Organization Name | NEW BEDFORD MEDICAL INVESTORS LLC |
Doing Business As | THE OAKS |
Address | 4525 Acushnet Ave, New Bedford, MA 02745 |
Phone Number | 508-998-7807 |
News Archive
A new type of HIV drug currently being tested works in an unusual way, scientists in the Molecular Medicine Partnership Unit, a collaboration between EMBL and Heidelberg University Hospital, have found.
Shire plc, the global specialty biopharmaceutical company, announces that a Luxembourg incorporated wholly-owned subsidiary of Shire plc will launch a voluntary public takeover offer for all the shares in Movetis NV, the Belgium-based European specialty gastrointestinal (GI) company. Movetis is listed on Euronext and focuses on discovering, developing and commercializing innovative treatments for GI conditions with a high unmet medical need.
Medication that specifically targets cancer cells and delivers its active agent without harming healthy cells - this is what doctoral students of the Magicbullet network will be working on from mid-2015. Bielefeld University is coordinating the programme for the development of "gentle" cancer treatment.
VistaGen Therapeutics, Inc., a stem cell technology company focused on drug discovery and development, today announced the successful completion of its initial Phase 1 safety study of AV-101, the Company's novel orally available prodrug candidate for treatment of neuropathic pain. Neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system, affects approximately 1.8 million people in the U.S.
A pain-free, organic and biodegradable drug delivery patch may be on the horizon for home health care patients soon.
› Verified 7 days ago
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
A new type of HIV drug currently being tested works in an unusual way, scientists in the Molecular Medicine Partnership Unit, a collaboration between EMBL and Heidelberg University Hospital, have found.
Shire plc, the global specialty biopharmaceutical company, announces that a Luxembourg incorporated wholly-owned subsidiary of Shire plc will launch a voluntary public takeover offer for all the shares in Movetis NV, the Belgium-based European specialty gastrointestinal (GI) company. Movetis is listed on Euronext and focuses on discovering, developing and commercializing innovative treatments for GI conditions with a high unmet medical need.
Medication that specifically targets cancer cells and delivers its active agent without harming healthy cells - this is what doctoral students of the Magicbullet network will be working on from mid-2015. Bielefeld University is coordinating the programme for the development of "gentle" cancer treatment.
VistaGen Therapeutics, Inc., a stem cell technology company focused on drug discovery and development, today announced the successful completion of its initial Phase 1 safety study of AV-101, the Company's novel orally available prodrug candidate for treatment of neuropathic pain. Neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system, affects approximately 1.8 million people in the U.S.
A pain-free, organic and biodegradable drug delivery patch may be on the horizon for home health care patients soon.
› Verified 7 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 0 |
Total Amount of Fines in Dollars | $0 |
Number of Payment Denials | 0 |
Total Number of Penalties | 0 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 18.57 | 14.46 |
Percentage of long-stay residents who lose too much weight | 5.41 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 56.25 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 1.26 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 4.92 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 1.32 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 2.45 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 97.24 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 12.89 | 14.2 |
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 94.74 | 83.88 |
Percentage of short-stay residents who newly received an antipsychotic medication | 1.73 | 1.79 |
Percentage of long-stay residents whose ability to move independently worsened | 35.49 | 17.09 |
Percentage of long-stay residents who received an antianxiety or hypnotic medication | 16.51 | 19.7 |
Percentage of high risk long-stay residents with pressure ulcers | 1.8 | 7.32 |
Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 99.47 | 95.98 |
Percentage of short-stay residents who made improvements in function | 73.1 | 67.99 |
Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 94.78 | 82.93 |
News Archive
A new type of HIV drug currently being tested works in an unusual way, scientists in the Molecular Medicine Partnership Unit, a collaboration between EMBL and Heidelberg University Hospital, have found.
Shire plc, the global specialty biopharmaceutical company, announces that a Luxembourg incorporated wholly-owned subsidiary of Shire plc will launch a voluntary public takeover offer for all the shares in Movetis NV, the Belgium-based European specialty gastrointestinal (GI) company. Movetis is listed on Euronext and focuses on discovering, developing and commercializing innovative treatments for GI conditions with a high unmet medical need.
Medication that specifically targets cancer cells and delivers its active agent without harming healthy cells - this is what doctoral students of the Magicbullet network will be working on from mid-2015. Bielefeld University is coordinating the programme for the development of "gentle" cancer treatment.
VistaGen Therapeutics, Inc., a stem cell technology company focused on drug discovery and development, today announced the successful completion of its initial Phase 1 safety study of AV-101, the Company's novel orally available prodrug candidate for treatment of neuropathic pain. Neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system, affects approximately 1.8 million people in the U.S.
A pain-free, organic and biodegradable drug delivery patch may be on the horizon for home health care patients soon.
› Verified 7 days ago
Brandon Woods Of New Bedford Location: 397 County Street, New Bedford, Massachusetts 02740 Phone: (508) 997-9396 | |
Hathaway Manor Extended Care Location: 863 Hathaway Road, New Bedford, Massachusetts 02740 Phone: (508) 996-6763 | |
Sacred Heart Nursing Home Location: 359 Summer Street, New Bedford, Massachusetts 02740 Phone: (508) 996-6751 | |
Savoy Nursing & Rehab Ctr Location: 670 County Street, New Bedford, Massachusetts 02740 Phone: (508) 994-2400 | |
New Bedford Jewish Convalescent Home, Inc Location: 200 Hawthorn Street, New Bedford, Massachusetts 02740 Phone: (508) 997-9314 |